Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | April 25, 2011 | April 28, 2011 |
| CytomX Therapeutics, Inc.CTMX · Entity 5124 | Director | June 15, 2022 | June 17, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 25, 2011 · Filed April 28, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,576 |
Reported balance
After 2011-04-25 transaction · row 1
1 source rowRow 1 · 2011-04-25 · Grant · Acquired 1,828 · Balance 17,576 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. |
| Nqso (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.69 · Expires 2021-04-25 | Direct | 5,000 |
Reported balance
After 2011-04-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2011-04-25 · Grant · Acquired 5,000 · Balance 5,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director.
CytomX Therapeutics, Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2032-06-14 | Direct | 25,000 |
Reported balance
After 2022-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2022 Filed Jun 17, 2022 16:05 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001567619-22-013071 · doc1.xml · derivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 18:43 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001567619-21-012365 · doc1.xml · derivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 17, 2020 Filed Jun 17, 2020 17:08 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001567619-20-012300 · doc1.xml · derivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 14:04 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $11.31 | $0.00 |
DisclosureSEC source: 0001567619-19-013825 · doc1.xml · derivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GiftCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-008682 · doc1.xml · nonDerivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Richlin Partners, LLC Disclosed balance after: 18,211 F2 · ownership.nature: Richlin Partners, LLC is an entity owned of record by the spouse of the Reporting Person. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 20:52 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GiftCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-008682 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 267,743 F1 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| April 08, 2019 Filed May 10, 2019 12:27 UTC Amendment | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GiftCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-010365 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,015 F1 · balance_after: The Form 4 filed on 4/10/2019 incorrectly reported a gift of 3,900 shares by the Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 ("Family Trust"). The 3,900 shares were gifted from the directly held shares, not the Family Trust. Additionally, previous filings made by the Reporting Person following 8/11/2016 inadvertently excluded the directly held shares from Table I. This Form 4/A amendment is filed to correct the aforementioned errors. Except as otherwise noted in this Form 4/A, all other information disclosed in the Reporting Person's original Form 4 filed with the Securities and Exchange Commission on 4/10/2019 was accurately reported. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 17:47 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $25.25 | $0.00 |
DisclosureSEC source: 0000899243-18-016816 · doc4.xml · derivative · entry 4 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-06-12 F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| March 26, 2018 Filed Mar 27, 2018 20:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 5,000 | $31.93 | $159,641.50 |
DisclosureSEC source: 0001140361-18-015300 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 271,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $31.70 to $32.18, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 19:01 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 16,181 | $30.00 | $485,465.60 |
DisclosureSEC source: 0001140361-18-012114 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 276,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 11:54 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 3,819 | $30.00 | $114,570.00 |
DisclosureSEC source: 0001140361-18-011514 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 292,824 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| January 05, 2018 Filed Jan 8, 2018 17:47 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 10,000 | $25.01 | $250,078.00 |
DisclosureSEC source: 0001140361-18-001261 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 296,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.21, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 17:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 5,000 | $22.29 | $111,425.50 |
DisclosureSEC source: 0001140361-17-047635 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 306,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.03 to $22.53, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| October 04, 2017 Filed Oct 6, 2017 12:18 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 10,000 | $24.27 | $242,680.00 |
DisclosureSEC source: 0001140361-17-037760 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 311,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.81 to $24.38, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| September 26, 2017 Filed Sep 27, 2017 16:12 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 5,000 | $17.30 | $86,476.00 |
DisclosureSEC source: 0001140361-17-036614 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 321,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.10 to $17.76, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| June 26, 2017 Filed Jun 27, 2017 16:57 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 5,000 | $14.61 | $73,050.00 |
DisclosureSEC source: 0001140361-17-026278 · doc1.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Frederick W. Gluck 1997 Family Trust dtd July 28, 1997 Disclosed balance after: 326,643 F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.84, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: The Reporting Person is a trustee of Frederick W. Gluck 1997 Family Trust dtd July 28, 1997. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 13:56 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0001140361-17-025786 · doc1.xml · derivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on June 20, 2018 subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 00:09 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $54.69 Strike: $54.69 | $273,450.00 |
DisclosureSEC source: 0001127602-11-013854 · form4.xml · derivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2021-04-25 Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 00:09 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-013854 · form4.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,576 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| September 08, 2010 Filed Sep 10, 2010 20:23 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 800 | $52.36 | $41,888.00 |
DisclosureSEC source: 0001127602-10-022847 · form4.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,748 Read SEC document |
| August 26, 2010 Filed Aug 27, 2010 16:25 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 800 | $51.76 | $41,404.00 |
DisclosureSEC source: 0001127602-10-022059 · form4.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,548 F1 · price: The price reported is an average price. The prices ranged from $51.74 to $51.78 per share. Full information regarding the number of shares sold at each separate price within the ranges set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 22:24 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $58.43 Strike: $58.43 | $292,150.00 |
DisclosureSEC source: 0001127602-10-012355 · form4.xml · derivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-04-26 Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 22:24 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-10-012355 · form4.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,348 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| April 28, 2009 Filed Apr 30, 2009 17:26 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $50.44 | $0.00 |
DisclosureSEC source: 0001127602-09-010049 · form4.xml · derivative · entry 3 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2016-04-28 Read SEC document |
| April 28, 2009 Filed Apr 30, 2009 17:26 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-09-010049 · form4.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,982 F1 · security: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had had less than three years of prior continuous services as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · derivative · entry 11 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2009-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $53.37 | $5,337.00 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 10 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,655 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $53.36 | $16,008.00 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 9 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,755 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,700 | $53.35 | $144,045.00 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 8 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,055 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,996 | $53.33 | $106,446.68 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 7 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,755 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 2,462 | $53.30 | $131,224.60 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 6 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,751 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 338 | $53.27 | $18,005.26 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 5 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,213 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $53.27 | $5,326.50 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 4 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,551 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 400 | $53.26 | $21,304.00 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 3 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,651 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 7,604 | $53.25 | $404,913.00 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,051 Read SEC document |
| January 27, 2009 Filed Jan 27, 2009 21:05 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 16,000 | $28.97 | $463,500.80 |
DisclosureSEC source: 0001127602-09-001733 · form4.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2008 Filed May 1, 2008 21:30 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $42.13 Strike: $42.13 | $210,650.00 |
DisclosureSEC source: 0001181431-08-028045 · rrd204678.xml · derivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2015-04-29 Read SEC document |
| April 29, 2008 Filed May 1, 2008 21:30 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 2,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-08-028045 · rrd204678.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,655 F1 · security: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director hah had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| April 26, 2007 Filed Apr 30, 2007 17:34 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $62.55 Strike: $62.55 | $312,750.00 |
DisclosureSEC source: 0001181431-07-027935 · rrd155980.xml · derivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2014-04-26 Read SEC document |
| April 26, 2007 Filed Apr 30, 2007 17:34 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,598 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-07-027935 · rrd155980.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,282 F1 · security: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| March 15, 2006 Filed Mar 17, 2006 22:07 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $74.89 | $0.00 |
DisclosureSEC source: 0001181431-06-018765 · rrd111627.xml · derivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2013-03-15 Read SEC document |
| March 15, 2006 Filed Mar 17, 2006 22:07 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,335 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-06-018765 · rrd111627.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,684 F1 · balance_after: Includes shares equivalent Restricted Stock Units, which were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 19991 Equity Incentive Plan, which were paid in shares of the Company's common stock on a one-to-one basis shortly after vesting, and which were previously identified as Restricted Stock Units on Table I. Read SEC document |
| February 17, 2006 Filed Feb 21, 2006 17:17 UTC | AMGEN INC AMGN · Entity 2832 | PurchaseCommon Stock | 4,705 | $74.48 | $350,427.46 |
DisclosureSEC source: 0001181431-06-013094 · rrd108658.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,349 Read SEC document |
| December 28, 2005 Filed Jan 23, 2006 18:57 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 4,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-06-004888 · rrd102110.xml · nonDerivative · entry 1 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,644 Read SEC document |
| March 15, 2005 Filed Mar 17, 2005 01:15 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.61 | $0.00 |
DisclosureSEC source: 0001181431-05-017371 · rrd72847.xml · derivative · entry 3 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2015-03-15 Read SEC document |
| March 15, 2005 Filed Mar 17, 2005 01:15 UTC | AMGEN INC AMGN · Entity 2832 | GrantRestricted Stock Units | 1,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-05-017371 · rrd72847.xml · nonDerivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,706 F1 · security: (DIR 03.15.05) The Restricted Stock Units ("RSUs") were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| March 15, 2004 Filed Mar 16, 2004 21:13 UTC | AMGEN INC AMGN · Entity 2832 | GrantNQSO (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $59.48 | $0.00 |
DisclosureSEC source: 0001181431-04-015906 · rrd36771.xml · derivative · entry 3 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2011-03-15 Read SEC document |
| March 15, 2004 Filed Mar 16, 2004 21:13 UTC | AMGEN INC AMGN · Entity 2832 | GrantRestricted Stock Units | 1,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001181431-04-015906 · rrd36771.xml · nonDerivative · entry 2 GLUCK FREDERICK W · CIK 0001184126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,643 F1 · security: (DIR 03.15.04) The Restricted Stock Units ("RSUs") were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one to one basis unless payment is otherwise deferred by the director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.